Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that Harold H. Shlevin, Ph.D., currently the Company’s Chief Operating Officer (COO), has been appointed Chief Executive Officer (CEO) and President to succeed Peter G. Traber, M.D., who has tendered his resignation as President, CEO and Chief Medical Officer.
Name: Peter G. Traber
Continent: North America
Company: Galectin Therapeutics Inc.
Position: CEO & President & Chief Medical Officer
Announcement Date: June 12, 2018, 10:00pm
Resignation Date: June 12, 2018, 10:00pm